| Revenue growth | Q2 +2% YoY; H1 +6% YoY |
|---|---|
| Margins | EBITDA margin 20% vs 22% YoY; Generics margin up 700bps |
| Demand visibility | Pertuzumab Brazil 10-year deal, US$400M TCV |
| Management confidence | Confident on stronger H2; no numeric guidance |
Growth
Revenue +2% YoY; Biosimilars +3%, Generics +10%, Services −9%. H1 revenue +6%, reported PAT +57% to ₹182 Cr.
Outlook
No numeric guidance. Management expects a stronger H2 from biosimilar launches, insulin capacity, generics and a Services recovery.
Risks
Services EBITDA down 18% YoY. Biosimilars margin hit by revenue-recognition timing. Q2 PBT ₹62 Cr vs ₹183 Cr.
Investor Presentation filed with NSE, NSE: BIOCON. Summary written with AI assistance from the document.
Biocon Ltd: key numbers
- Share price
- ₹345.10
- Market cap
- ₹56,241 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 113.5×Sector 41.3×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Results Update
Biocon reported Q2FY27 consolidated total income of ₹4,423 crore with EBITDA at ₹865 crore. Net profit was ₹41 crore as Biopharma revenue grew 5% YoY.
Biocon Q2 FY27 Results: Net Profit ₹56.7 Cr, Down 57.3% YoY
Biocon Ltd reported revenue from operations of ₹4,389 Cr (+2.2% YoY) and net profit of ₹56.7 Cr (-57.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.7 Cr · -57.3% YoY
Biocon Board Meeting Date
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Other Announcement
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon Partnership
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
- From
- Genentech